This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
24/7 Access
Digital & In-Person
Menu

Soren Ostergaard, Ph.D.
Principal Scientist at Novo Nordisk A/S
Speaker

Agenda Sessions

  • Design of Long-acting Y2 Receptor Selective PYY3-36 Analogues

    On Demand - Premium Only
    View Session

At this event

Prev
Next
Michael Panzara, M.D.
Chief Medical Officer
Wave Life Sciences

See Soren at TIDES: Oligonucleotide & Peptide Therapeutics Content Hub